# Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa

> **NCT00627640** · PHASE3 · COMPLETED · sponsor: **Newron Pharmaceuticals SPA** · enrollment: 549 (actual)

## Conditions studied

- Idiopathic Parkinson's Disease

## Interventions

- **DRUG:** Safinimide 50-100 mg/day
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT00627640
- **Lead sponsor:** Newron Pharmaceuticals SPA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2012-01
- **Final completion:** 2012-03
- **Target enrollment:** 549 (ACTUAL)
- **Last updated:** 2013-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00627640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00627640, "Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00627640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*